Literature DB >> 3871423

A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis.

R A Lake, A Morgan, B Henderson, N A Staines.   

Abstract

The interactions of DNA, monoclonal anti-DNA autoantibodies and isolated purified components of the extracellular matrix (ECM) were studied in a solid phase model system. Binding of DNA to each of the components was assessed using monoclonal antibody and enzyme conjugated antiglobulin in direct binding and inhibition assays. Each of the genetically distinct collagens (Types I-IV), proteoglycan monomer and laminin, bound ssDNA, but dsDNA bound significantly only to fibronectin. When used in an inhibition system, fibronectin linked DNA and anti-DNA antibodies to the collagens; it had a differential effect on the binding of ssDNA and dsDNA to a Type IV collagen matrix, the most striking feature being a 100 fold increase in dsDNA binding to Type IV collagen in the presence of fibronectin. It is likely that fibronectin binds dsDNA to collagen by separate binding domains for these molecules, and that this may be involved in the deposition of DNA in kidneys in some forms of glomerulonephritis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871423      PMCID: PMC1453499     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  19 in total

1.  Localization of the nephrotoxic antigen within the isolated renal glomerulus.

Authors:  C A KRAKOWER; S A GREENSPON
Journal:  AMA Arch Pathol       Date:  1951-06

2.  Enzyme-linked immunosorbent assay, Elisa. 3. Quantitation of specific antibodies by enzyme-labeled anti-immunoglobulin in antigen-coated tubes.

Authors:  E Engvall; P Perlmann
Journal:  J Immunol       Date:  1972-07       Impact factor: 5.422

Review 3.  Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine.

Authors:  E M Tan
Journal:  Adv Immunol       Date:  1982       Impact factor: 3.543

4.  Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA.

Authors:  W Emlen; M Mannik
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

5.  Ultrastructural localisation of fibronectin in mouse kidney.

Authors:  A J Dixon; J Burns
Journal:  J Pathol       Date:  1982-09       Impact factor: 7.996

6.  DNA-binding domains of fibronectin probed using Western blots.

Authors:  S O Hoch
Journal:  Biochem Biophys Res Commun       Date:  1982-06-30       Impact factor: 3.575

7.  Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus.

Authors:  J Holian; I D Griffiths; D N Glass; R N Maini; J T Scott
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

8.  Immunopathologic studies of systemic lupus erythematosus. II. Antinuclear reaction of gamma-globulin eluted from homogenates and isolated glomeruli of kidneys from patients with lupus nephritis.

Authors:  C Krishnan; M H Kaplan
Journal:  J Clin Invest       Date:  1967-04       Impact factor: 14.808

9.  Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

Authors:  U E Nydegger; P H Lambert; H Gerber; P A Miescher
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

10.  Glomerulonephritis induced by pre-formed immune complexes containing monoclonal antibodies of defined affinity and isotype.

Authors:  A M Lew; N A Staines; M W Steward
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

View more
  12 in total

1.  LDL-mediated interaction of DNA and DNA-anti-DNA immune complexes with cell surface.

Authors:  A E Kabakov; V A Saenko; A M Poverenny
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

2.  DNA-binding antibodies derived from autoimmune MRL mice fail to induce clinical changes when administered to healthy animals.

Authors:  R Lake; N Staines
Journal:  Agents Actions       Date:  1986-12

3.  Specific increases in urinary excretion of anti-DNA antibodies in lupus mice induced by lysozyme administration: further evidence for DNA-anti-DNA immune complexes in the pathogenesis of nephritis.

Authors:  T Yamamoto; M Nagase; A Hishida; N Honda
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

4.  Role of fibronectin on the clearance and tissue uptake of antigen and immune complexes in rats.

Authors:  F G Cosio; A P Bakaletz
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

5.  A monoclonal DNA-binding autoantibody causes a deterioration in renal function in MRL mice with lupus disease.

Authors:  R A Lake; N A Staines
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

6.  Characterization and pathological significance of monoclonal DNA-binding antibodies from mice with experimental malaria infection.

Authors:  C M Lloyd; I Collins; A J Belcher; N Manuelpillai; A O Wozencraft; N A Staines
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

7.  Shared idiotypes are expressed on mouse and human anti-DNA autoantibodies.

Authors:  A Morgan; D A Isenberg; Y Naparstek; J Rauch; D Duggan; R Khiroya; N A Staines; A Schattner
Journal:  Immunology       Date:  1985-11       Impact factor: 7.397

Review 8.  Lupus nephritis in childhood and adolescence.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

9.  Role of DNA-binding antibodies in kidney pathology associated with murine malaria infections.

Authors:  A O Wozencraft; C M Lloyd; N A Staines; V J Griffiths
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

10.  Ligand recognition by murine anti-DNA autoantibodies. II. Genetic analysis and pathogenicity.

Authors:  P C Swanson; R L Yung; N B Blatt; M A Eagan; J M Norris; B C Richardson; K J Johnson; G D Glick
Journal:  J Clin Invest       Date:  1996-04-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.